This podcast explores macular telangiectasia (MacTel), a rare and progressive retinal disease, with a focus on advancing early detection, appropriate treatment, and health system coordination. Retina specialist Dr. Jay Chhablani discusses the shift in understanding MacTel as a neurodegenerative—not vascular—condition, highlighting the limitations of anti-VEGF therapy and the significance of a newly approved, durable implant that targets neuroprotection. The discussion outlines the importance of benefit design that facilitates timely access, supports multidisciplinary care, and emphasizes early intervention to prevent irreversible vision loss. Practical payer strategies—including reducing artificial barriers and prioritizing education—are addressed to optimize outcomes.

This activity is certified for CME/CNE/CPE credit. To participate and earn 

credit, visit us at https://www.impactedu.net/mactel-strategies-ce/.